Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912754 | 0.83 | ESR1 (0.43) | ESR1THRATHRBDAOSLC6A2 | |
| SCHEMBL562364 | 0.83 | SLC6A2 (0.55) | RIPK1HTTALDH1A1MAOAMAOB | |
| SCHEMBL9027451 | 0.83 | RIPK1 (0.45) | RIPK1HTTALDH1A1MAOAMAOB | |
| SCHEMBL1912677 | 0.83 | ESR1 (0.43) | ESR1RIPK1THRATHRBDAO | |
| SCHEMBL565080 | 0.83 | RIPK1 (0.45) | ESR1RIPK1HTTALDH1A1MAOA | |
| SCHEMBL23790349 | 0.83 | ESR1 (0.43) | ESR1RIPK1THRATHRBDPP4 | |
| SCHEMBL13905164 | 0.81 | CYP1A2 (0.47) | ESR1RIPK1ALDH1A1MAOAMAOB | |
| SCHEMBL13821426 | 0.81 | RIPK1 (0.47) | RIPK1HTTALDH1A1MAOAMAOB | |
| SCHEMBL13788319 | 0.81 | RIPK1 (0.47) | ESR1RIPK1HTTALDH1A1MAOA | |
| SCHEMBL2600030 | 0.81 | CNR2 (0.43) | ESR1HTTALDH1A1DAOSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230128006-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | APTINYX INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128006-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | APTINYX INC. | 2023-04-27 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ESR1 1088/4885RIPK1 3010/4885HTT 3632/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | ESR1 2227/4885RIPK1 1219/4885HTT 3402/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | ESR1 1581/4885RIPK1 1209/4885HTT 1695/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | ESR1 4551/4885RIPK1 158/4885HTT 3983/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ESR1 1088/4885RIPK1 3010/4885HTT 3632/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | ESR1 4857/4885RIPK1 462/4885HTT 4703/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | ESR1 3881/4885RIPK1 4/4885HTT 3599/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | ESR1 4439/4885RIPK1 242/4885HTT 923/4885 |
| US-20230128006-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | GRIN1, GRIN2A, GRIN2C | ESR1 1714/4885RIPK1 1859/4885HTT 1545/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ESR1 4369/4885RIPK1 4519/4885HTT 1110/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | ESR1 4482/4885RIPK1 1360/4885HTT 2264/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | ESR1 2854/4885RIPK1 3137/4885HTT 3207/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | ESR1 534/4885RIPK1 2459/4885HTT 300/4885 |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | ESR1 1251/4885RIPK1 4856/4885HTT 1967/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | ESR1 2358/4885RIPK1 3408/4885HTT 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.